Update - Early Access to Medicines Scheme for remdesivir in the treatment of COVID-19. Implementation of the scheme and management of supply

MHRA Central Alerting System team Coronavirus alerts banner

Update - Early Access to Medicines Scheme for remdesivir in the treatment of COVID-19. Implementation of the scheme and management of supply

This is an update to the alert we issued on 26 May regarding remdesivir.

The access criteria for the remdesivir EAMS have been amended to reflect developing clinical experience and knowledge of demand and changes in medicine supply. For the NHS in England new registrations to the EAMS have now closed: initial stock allocations have been made. Trusts must retrospectively complete a remdesivir Blueteq form to register patients who have received remdesivir in order to receive further medicine supply.

Further information can be found in the attached alert.

Access the alert here

Thank you,
Central Alerting System team, MHRA

If you would like to share this with a friend or colleague, hit the Forward button or send them this link to view the email in a browser.

Unsubscribe or change your email address at any time on your subscriber preferences page.

If you have questions or problems with the subscription service, please visit subscriberhelp.govdelivery.com.

All other enquiries can be directed to safetyalerts@subscriptions.mhra.gov.uk

This is an automatically generated email. Please do not reply directly to this notification.
This service is provided to you at no charge by the Medicines and Healthcare products Regulatory Agency.